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http://dx.doi.org/10.1016/j.pedneo.2Mitochondrial DNA (mtDNA) deletion is a rare occurrence that results in defects to oxidative
phosphorylation. The common clinical presentations of mtDNA deletion vary but include mito-
chondrial myopathy, Pearson syndrome, Kearns-Sayre syndrome, and progressive external
ophthalmoplegia. Here, we report the case of a 10-year-old boy who presented with progres-
sive deterioration of his clinical status (which included hypoglycemia, short stature, sensori-
neural hearing loss, retinitis pigmentosa, and chronic gastrointestinal dysmotility) that
progressed to acute deterioration with pancreatitis, Fanconi syndrome, lactic acidosis, and
acute encephalopathy. Following treatment, the patient was stabilized and his neurological
condition improved. Through a combination of histological examinations and biochemical
and molecular analyses, mitochondrial disease was confirmed. A novel 3670-base pair deletion
(deletion of mtDNA nt 7,628-11,297) was identified in the muscle tissue. A direct repeat of
CTACT at the breakpoints was also detected.
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with metabolic acidosis (pH 7.27; HCO3 18.6 mEq/L),The mitochondrion is an organelle that is critically involved
in the production of energy in cells. The mitochondrion
contains a separate genome that consists of circularized,
double-stranded DNA that is 16,569 base pairs (bp) long.1
Mitochondrial DNA contains 37 genes that encode 13 poly-
peptide components of the mitochondrial oxidative phos-
phorylation machinery, two ribosomal RNA molecules, and
a set of 22 transfer RNA molecules.2 In addition, a 1.1-
kilobase (kb) D-loop (noncoding region) regulates tran-
scription and replication of mitochondrial DNA (mtDNA).2
Deletions within mtDNA result in defects to the oxidative
phosphorylation pathway that result in clinical
manifestations.2
Mitochondrial myopathy (MM) and three mitochondrial
syndromesdPearson syndrome (MIM #557000) presenting in
infancy, Kearns-Sayre syndrome (KSS; MIM #530000) pre-
senting in childhood to early adulthood, and progressive
external ophthalmoplegia (PEO; MIM #157640) presenting in
later lifedare associated with large mtDNA deletion
syndrome.2,3 However, the clinical manifestations of
mtDNA deletion syndrome may be incomplete, extensive,
or overlap such that they cannot be classified as any of
these three diseases. In such situations, these cases are
classified as multisystemic manifestations4,5; these multi-
systemic manifestations have been observed in younger
patients (<10 years of age).4
Around 120e150 different large mtDNA deletions have
been reported as clinically symptomatic.1,3 The size of
these deletions range from 1.3e11.9 kb.3,5,6 The majority
(60%) of these deletions result from replication errors at the
sites of short direct-repeat sequences.5 For example, a 13-
nucleotide repeat sequence between base pairs 8469 and
13,447 results in the common 4977-bp deletion that pres-
ents in 30e50% of KSS patients.5,7 However, other sites of
sequence homology can also cause large deletions. Here,
we report the case of a 10-year-old boy who presented with
the multisystemic manifestations of mtDNA deletion.
Molecular analysis identified a novel 3670-bp deletion in the
mtDNA (deletion of mtDNA nt 7,628e11,297). A direct
repeat of CTACT at the breakpoints was also detected.
2. Case Report
Our patient, a 10-year-old boy, was the first child of
a nonconsanguineous marriage whose mother was 26 years
old. His birth weight was 3250 g (15e50th percentile).
Anhidrosis with dry skin had been noted since infancy.
According to his mother, his development was normal. He
developed recurrent hypoglycemia before 3 years of age.
Retinitis pigmentosa and growth hormone deficiency
(maximum growth hormone level was 7 ng/mL after cloni-
dine stimulation) that were unresponsive to growth
hormone therapy had been observed since 4 years of age.
At 7 years of age, bilateral hearing loss, recurrent
lactic acidemia, hypokalemia (1.9 mEq/L), and hypo-
phosphatemia (1.18 mMol/L) were observed.
At 10 years of age, the patient was diagnosed with acute
pancreatitis (1616 U/L amylase; 4640 U/L lipase), which
improved following supportive care. Meanwhile, Fanconisyndrome with type II renal tubular acidosis manifesting
hypokalemia (1.9 mEq/L), hypocalcemia (2.12 mM), hypo-
phosphatemia (1.8 mg/dL), hypomagnesemia (1.0 mg/dL),
and a high urine anion gap (þ28: normal: -10 to þ10) were
also observed in this patient. These symptoms partially
improved with vitamin D, potassium phosphate, and sodium
bicarbonate supplementation, but metabolic acidosis per-
sisted. There were no atrioventricular blocks seen on his
electrocardiogram (ECG). Echocardiography revealed
mitral valve prolapse with mild mitral regurgitation.
While recovering from pancreatitis, a fever episode
further deteriorated the boy’s clinical status, which was
followed by progressive fatigue, lactic acidosis (7 mM;
normal < 2 mM), and consciousness disturbance with
Kussmaul respiration. Within 2 days, he rapidly progressed
into a coma (Glasgow coma scale: E1V1M1) and intubation
was necessary. Brain magnetic resonance imaging (MRI)
with T2-weighted imaging at the time of deterioration
revealed high signal intensities in the upper cerebellar
vermis, thalami, and tegmentum of the midbrain, sub-
stantia nigra, dorsal pons, putamen, globus pallidum,
caudate nuclei, left cerebellar subcortical area, and the
left frontal peripheral parenchyma (Figure 1A). Magnetic
resonance spectroscopy (MRS) showed an accumulation of
lactate peaks at a concentration of approximately 1.3 ppm
(Figure 1B). Acute ischemic changes in the cerebellar ver-
mis, brain stem, and deep gray matter were suspected
(Figure 1C). Suspecting mitochondrial disorder with acute
ischemic changes, intravenous carnitine (100 mg/kg/day),
oral ubiquinone (10 mg/kg/day), L-arginine (200 mg/kg/
day), and mannitol (40 cc of a 20% solution every 6 hours)
were administered. Sodium bicarbonate was aggressively
administered in order to treat the patient’s metabolic
acidosis. The patient’s consciousness improved to E4VTM6
the next day, and his blood lactate level (2.1 mM)
normalized. After recovering consciousness, the patient’s
muscle power was still so poor that he could only flex his
fingers and blink. Overall, recovery was slow and poor
gastrointestinal motility was observed. A nasoduodenal
tube (ND) was inserted, and the patient’s condition,
including muscle power, dramatically improved with
enteral feeding. Extubation was performed 5 weeks after
admission, and bilevel positive airway pressure (BiPAP) was
maintained for 2 weeks thereafter. The ND tube was
replaced with a nasogastric tube, which the patient toler-
ated well. He was discharged 80 days after admission,
although his course of potassium chloride, sodium bicar-
bonate, carnitine, L-arginine, ubiquinone, calcium
carbonate, and vitamin D3 was continued. At the time of
discharge, the patient was able to sit without aid but
lacked fine motor control in his hands. He could listen and
talk without difficulty using hearing aids.
To further evaluate this potential mitochondrial
disorder, a muscle biopsy was performed during the period
of acute deterioration. At that time, his creatine kinase
level was 84 U/L. The results indicated the absence of
ragged red fibers. However, 95% of the 60 observed mito-
chondria appeared to have abnormal architecture with
electron-dense aggregates (Figure 2). Analysis of mito-
chondrial electron transfer chain activity revealed mito-
chondrial proliferation (citrate synthase activity was 138%
Figure 1 Brain magnetic resonance imaging at the time of deterioration in our patient. (A) High signal intensity on T2-weighted
imaging in the upper cerebellar vermis, left cerebellar subcortical area, dorsal pons, both thalami, putamen, globus pallidum,
caudate nuclei, both tegmentum of the midbrain, both substantia nigra, and left frontal peripheral parenchyma were noted.
(B) Magnetic resonance spectroscopy showing a remarkable accumulation of lactate peaks around 1.3 ppm (arrow). (C) Decreased
apparent diffusion coefficients are evident in the heads of both caudate nuclei and both basal ganglia (low-signal areas), which are
suggestive of a recent ischemic event.
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around 47e82% of the control mean after adjusting for
citrate synthase activity (Table 1). mtDNA derived from the
muscle (not blood) showed a large 3670-bp deletion (dele-
tion of mtDNA 7628e11297 nt; Figure 3A). Ten genes were
within the deletion region, including COX II, COX III, tRNA
(TRNR and TRNK), ATPase 6, ATPase 8, and NADH dehy-
drogenase (ND3, ND4, and ND4L).
We analyzed the sequence homology of the 49 nucleo-
tides surrounding the deletion site junction and found
a region of 57% sequence identity that contained a direct
repeat of CTACT (Figure 3B). This suggests a common class
I deletion, where the deletion occurs at a site containing
a short direct-repeat sequence.5 We did not find this
breakpoint in the MitoMap or in any PubMed publica-
tions1,5; therefore, we consider this to be a novel mtDNA
deletion.3. Discussion
The 10-year-old boy described in this study has shown
progressive systemic manifestations of mitochondrial cyt-
opathy since 3 years of age. He has suffered fromanhidrosis, hypoglycemia, growth hormone deficiency,
retinitis pigmentosa, hearing loss, lactic acidemia, gastro-
intestinal dysmotility, Fanconi syndrome, pancreatitis, and
acute ischemic changes in the brain. According to the
modified diagnostic criteria for mitochondrial disorders,7
our patient fits two major criteria: (1) clinical symptoms
of mitochondrial cytopathy with a progressive, unexplained
combination of multisystemic symptoms; and (2) molecular
identification of an mtDNA deletion. Therefore, he fulfilled
the criteria for the diagnosis of a mitochondrial disorder.
However, because ophthalmoplegia, heart block, and
hematopoietic problems were not observed and his creati-
nine kinase levels were normal (47e169 U/L), he did not fit
the diagnosis of Pearson syndrome or KSS. Multisystemic
manifestations of mitochondrial disease might be the best
description of this case. Multisystemic involvement
accounts for around 45% of the patients with mtDNA dele-
tion syndrome that manifest in childhood (6e20 year of
age).5 This implies that the clinical presentations of the
majority of pediatric patients with mtDNA deletion
syndromes are atypical.
In our case, although we identified an mtDNA deletion in
the muscle, the assay did not identify defects in the elec-
tron transport chain in the muscle (47e82% of the control
Figure 2 Muscle biopsy of the patient. (A) Hematoxylin and eosin staining revealed marked variation in the size of the muscle
fibers. (B) ATPase staining revealed positive muscle fibers, mainly angular and atrophic type II fibers. (C) Gomori trichrome staining
did not show ragged red fibers. (D) Electron microscopy revealed abnormal architecture and morphology with many electron-dense
aggregates in the mitochondria.
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mutations with a biochemical phenotype (e.g., electron
transfer chain activities) have been reported.8,9 For
example, Brautbar et al reported three cases of patients
with the G13513A mutation, but in only one case was lowTable 1 Respiratory chain enzyme activity in muscle.
Enzyme
NADH: Ferricyanide dehydrogenase (complex I)
NADH: Cytochrome c reductase (complex IþIII)
Total
Rotenone sensitive
Succinate dehydrogenase (complex II)
Cytochrome c oxidase (complex IV)
CS
Ratio
Complex I/CS
Complex IþIII/CS (total)
Complex IþIII/CS (rotenone)
Complex II/CS
Complex IV/CS
* Data are presented as nmol/min/mg-protein. CS Z citrate synthacomplex I activity identified.8 It has been proposed that
complicating variables, such as differences in genetic
backgrounds, mtDNA haplotypes, and environmental
factors in conjunction with the degree of heteroplasmy of
the mtDNA deletion in the individual, result in variations inPatient* (% of control mean) Control  SD*
423.32 (92) 458.61  66.08
39.76 (96) 41.42  6.11
10.30 (62) 16.57  4.81
14.52 (87) 16.63  2.21
80.08 (94) 85.59  19.75
190.49 (138) 137.72  39.62
Patient (% of control mean) Control  SD
2.22 (73) 3.03  0.65
0.21 (82) 0.25  0.07
0.05 (47) 0.11  0.04
0.08 (52) 0.15  0.04
0.42 (67) 0.62  0.15
se; SD Z standard deviation.
Figure 3 (A) A large 3670-bp deletion (7,628e11,297 nt) was identified in muscle tissue-derived DNA. (B) Sequence homology
analysis of 49 nucleotides surrounding the deletion junction revealed a direct repeat of CTACT at the breakpoints. Arrowheads
indicate the breakpoints.
268 H.-M. Liu et almitochondrial electron transport chain enzyme activities
between patients.8
The encouraging part of this case is that this boy
recovered from a severe and extensive cerebral ischemic
episode under our managed care. Acute decompensation of
mitochondrial disorders is often triggered by infections or
other forms of stress. In this case, infection may have been
the triggering factor. However, adequate supportive care
seems to have been helpful. It is surprising that he was able
to go back to nasogastric tube feeding after insertion of the
ND tube. This phenomenon, in conjunction with improve-
ment in his neurological condition, indicates that with
adequate medical treatment the recovery of mitochondrial
respiratory chain function is possible.
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